NeOnc subsidiary NuroMENA signs MSA with M42's IROS for UAE Phase 2b/3 trial of NEO100; board expanded

NEONC TECHNOLOGIES HOLDINGS, INC.

MSA with IROS (affiliate of M42 and Mubadala) covers clinical research services in UAE for CNS cancer therapies.
First work order: Phase 2b/3 study of intranasal NEO100 in progressive/recurrent GBM and Grade III astrocytomas.
Estimated budget of $2.4M in service fees plus $0.1M pass-through costs, milestone-based payments.
NuroMENA board expands with Waleed K. Al Ali (CEO of Quazar Investment) and its Chairman, alongside Amir Heshmatpour and others.
Company retains all IP and data from studies under MSA; agreement governed by Abu Dhabi Global Market law.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.